Insider · CIK 0001971798
David J. Wambeke
Files at DMAC (DiaMedica Therapeutics Inc.), NMTC (NEUROONE MEDICAL TECHNOLOGIES Corp). First filing Nov 16, 2023, latest Sep 8, 2026.
In brief
David J. Wambeke files SEC Form 4 as officer at NMTC (NEUROONE MEDICAL TECHNOLOGIES Corp), and also at DMAC (DiaMedica Therapeutics Inc.). Since Nov 16, 2023, David J. Wambeke has reported 3 open-market buys worth $787k and 0 open-market sells worth $0, the latest filed on Sep 8, 2026.
A track record needs three past buys with six months of prices behind them; David J. Wambeke has 1, so none is measured yet.
The newest scored trade: bought $67k of NMTC on Aug 27, 2026, filed Sep 8, 2026, scored 26 (weak). In the last 12 months: 2 buys worth $737k and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
NMTC: NEUROONE MEDICAL TECHNOLOGIES Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
DMAC: DiaMedica Therapeutics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | NMTCbuy NEUROONE MEDICAL TECHNOLOGIES Corp | $67k 33,333 shares | +20% | - | |
| 51Moderate | NMTCbuy NEUROONE MEDICAL TECHNOLOGIES Corp | $670k 1,000,000 shares | - | +56% from low-40% from high | |
| 30Weak | DMACbuy DiaMedica Therapeutics Inc. | $49k 20,000 shares | +4% | +111% from low-46% from high |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | POpen-market purchase Common Stock | +33,333 | $2.01 | $67k | 199,999 | 36 d ago |
| Aug 28, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | AGrant or award Option to Purchase Common Stockderivative | +35,000 | $0.00 | $0 | 35,000 | 36 d ago |
| Mar 1, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | POpen-market purchase Common Stock | +1,000,000 | $0.67 | $670k | 1,000,000 | Mar 3, 2026 |
| Mar 1, 2026 | NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | AGrant or award Option to Purchase Common Stockderivative | +500,000 | $0.00 | $0 | 500,000 | Mar 3, 2026 |
| Jun 1, 2025 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jun 3, 2025 |
| Jun 1, 2024 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Jun 3, 2024 |
| Nov 16, 2023 | DMAC DiaMedica Therapeutics Inc. | POpen-market purchase Voting Common Shares, no par value per share | +20,000 | $2.46 | $49k | 527,114 | Nov 16, 2023 |
Questions about David J. Wambeke
Answered from the filings on this page, as of the latest one.
Is David J. Wambeke buying or selling?
In the last 12 months David J. Wambeke reported 2 open-market buys worth $737k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $67k of NMTC on Aug 27, 2026. Grants, option exercises and tax withholding are not counted.
How did David J. Wambeke's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David J. Wambeke has 1.
Where does David J. Wambeke file Form 4?
David J. Wambeke has filed Form 4 at NMTC (NEUROONE MEDICAL TECHNOLOGIES Corp) as Chief Business Officer; DMAC (DiaMedica Therapeutics Inc.) as Chief Business Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.